OptimizeRx Cuts Revenue Guidance Again as Sales Fall for Third Straight Quarter
Company Background
OptimizeRx operates a healthcare technology platform that connects pharmaceutical and life sciences companies with physicians through a network spanning more than 450 electronic health record and e-prescribing systems. The company generates revenue primarily by enabling targeted digital engagement at the point of care — placing content, clinical decision support, and advertising in front of verified healthcare professionals during clinical workflows. With a market capitalization of approximately $167M, it occupies a niche position between traditional pharma sales infrastructure and digital media buying.
After years of losses, 2025 marked a turning point: full-year revenue reached a record $109.4M, up 19% year over year, and adjusted EBITDA hit $24.3M. Management celebrated achieving the "Rule of 40" benchmark. That momentum, however, did not carry into 2026. The first quarter brought a 10% year-over-year revenue decline, the second a 30% drop — which management attributed to spending pullbacks at a small number of large pharmaceutical customers, partly linked to uncertainty around the federal government's most-favored-nation drug pricing policy. Through nine months of 2026, revenue totals $62.0M versus $77.2M in the same period of 2025, a 20% decline.
The company has taken visible steps to reduce its cost base. A debt refinancing in May 2026 replaced a Blue Torch Finance term loan with a $35M Fifth Third Bank facility at materially lower rates, and aggressive prepayments have reduced the outstanding principal to $10.4M. Gross margins have improved significantly as management deliberately exited lower-margin managed-services revenue. The balance sheet looks cleaner than it has in years — but the top line has not responded.
What Was Disclosed
Third-quarter revenue of $21.6M fell 17% from $26.1M in Q3 2025, the third consecutive quarter of double-digit year-over-year decline. GAAP net income was $1.2M, or $0.06 per diluted share, up from $0.8M a year earlier. Adjusted EBITDA improved to $6.3M from $5.1M, with the adjusted EBITDA margin expanding roughly 900 basis points to approximately 29% — a function of lower-cost product mix and ongoing expense discipline rather than revenue growth. Cash at September 30 stood at $22.3M, and operating cash flow for the nine months ended September 30 was $12.9M.